{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:29:46Z","timestamp":1788953386925,"version":"build-2803163510"},"reference-count":78,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy (prophylaxis or preemptive treatment) depends on the donor\/recipient sero-status but may vary between institutions. We conducted a series of consultations and roundtable discussions with German liver transplant center representatives. Based on 20 out of 22 centers, we herein summarize the current approaches to CMV prevention and treatment in the context of liver transplantation in Germany. In 90% of centers, transient prophylaxis with ganciclovir or valganciclovir was standard of care in high-risk (donor CMV positive, recipient CMV naive) settings, while preemptive therapy (based on CMV viremia detected during (bi) weekly PCR testing for circulating CMV-DNA) was preferred in moderate- and low-risk settings. Duration of prophylaxis or intense surveillance was 3\u20136 months. In the case of CMV infection, immunosuppression was adapted. In most centers, antiviral treatment was initiated based on PCR results (median threshold value of 1000 copies\/mL) with or without symptoms. Therefore, German transplant centers report similar approaches to the prevention and management of CMV infection in liver transplantation.<\/jats:p>","DOI":"10.3390\/jcm9082352","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T11:26:01Z","timestamp":1595503561000},"page":"2352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers"],"prefix":"10.3390","volume":"9","author":[{"given":"Cornelius","family":"Engelmann","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charit\u00e9 University Medicine Berlin, 13353 Berlin, Germany"},{"name":"Institute for Liver and Digestive Health, University College London, Royal Free Campus, London NW32PF, UK"},{"name":"Section Hepatology, Clinic for Gastroenterology and Rheumatology, University Hospital Leipzig, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sterneck","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Heinz","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University of Heidelberg, 69117 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Templin","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Zopf","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, University of Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Denk","sequence":"additional","affiliation":[{"name":"Medical clinic and policlinic II, Campus Grosshadern, Ludwig Maximilians University (LMU), 80333 Munich, Germany"},{"name":"Transplantation Center Munich, University Hospital, 81377 LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Eurich","sequence":"additional","affiliation":[{"name":"Department of Surgery Campus Charit\u00e9 Mitte\/Campus Virchow-Klinikum, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Pratschke","sequence":"additional","affiliation":[{"name":"Department of Surgery Campus Charit\u00e9 Mitte\/Campus Virchow-Klinikum, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Medicine II, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of General, Visceral, Thoracic, Transplant and Pediatric Surgery, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin-Walter","family":"Welker","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital Frankfurt, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hepatology, University of Mainz, 55101 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Knipper","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Nierhoff","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital K\u00f6ln, 50937 K\u00f6ln, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lorf","sequence":"additional","affiliation":[{"name":"Clinic for General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"J\u00e4ckel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology &amp; Endocrinology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Michael","family":"Hau","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplantation, Thoracic, and Vascular Surgery, University Hospital Leipzig, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung Yu","family":"Tsui","sequence":"additional","affiliation":[{"name":"Section of Oncological Surgery and Transplantation, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristoteles","family":"Perrakis","sequence":"additional","affiliation":[{"name":"Department of General, Visceral, Vascular and Transplant Surgery, University Hospital Magdeburg, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-0296","authenticated-orcid":false,"given":"Hans-J\u00fcrgen","family":"Schlitt","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Herzer","sequence":"additional","affiliation":[{"name":"Knappschafts-Hospital Bad Neuenahr, Deutsche Rentenversicherung, Knappschaft-Bahn-See, 53474 Bad Neuenahr-Ahrweiler, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charit\u00e9 University Medicine Berlin, 13353 Berlin, Germany"},{"name":"Department of Medicine III, University Hospital Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/lt.24078","article-title":"Risk factors for cytomegalovirus reactivation after liver transplantation: Can pre-transplant cytomegalovirus antibody titers predict outcome?","volume":"21","author":"Bruminhent","year":"2015","journal-title":"Liver Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MOT.0000000000000433","article-title":"Cytomegalovirus in liver transplant recipients","volume":"22","author":"Herman","year":"2017","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.3748\/wjg.v22.i12.3412","article-title":"Two strategies for prevention of cytomegalovirus infections after liver transplantation","volume":"22","author":"Simon","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jceh.2017.05.011","article-title":"Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management","volume":"7","author":"Yadav","year":"2017","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: Liver transplantation","volume":"64","author":"Russo","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1179\/2047773213Y.0000000114","article-title":"Human cytomegalovirus detection by real-time PCR and pp65-antigen test in hematopoietic stem cell transplant recipients: A challenge in low and middle-income countries","volume":"107","author":"Breda","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"ref_7","first-page":"25","article-title":"The cytomegalovirus antigenemia assay: A plea for standardization","volume":"99","author":"The","year":"1995","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/JCM.36.12.3585-3589.1998","article-title":"Standardization of the Human Cytomegalovirus Antigenemia Assay by Means of In Vitro-Generated pp65-Positive Peripheral Blood Polymorphonuclear Leukocytes","volume":"36","author":"Gerna","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1128\/JCM.38.12.4485-4491.2000","article-title":"Diagnostic Implications of Human Cytomegalovirus Immediate Early-1 and pp67 mRNA Detection in Whole-Blood Samples from Liver Transplant Patients Using Nucleic Acid Sequence-Based Amplification","volume":"38","author":"Blok","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1600-6143.2004.00510.x","article-title":"Prospective Evaluation of the Clinical Utility of Different Methods for the Detection of Human Cytomegalovirus Disease after Liver Transplantation","volume":"4","author":"Seehofer","year":"2004","journal-title":"Am. J. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/QCO.0b013e32821f6010","article-title":"Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients","volume":"20","author":"Drew","year":"2007","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-6143.2008.02513.x","article-title":"For the American Society of Transplantation Infectious Diseases Community of Practice and the Canadian Society of Transplantation Interlaboratory Comparison of Cytomegalovirus Viral Load Assays","volume":"9","author":"Pang","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.eimc.2011.05.022","article-title":"GESITRA-SEIMC\/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients","volume":"29","author":"Caston","year":"2011","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"ref_14","unstructured":"DGFV (2020, June 02). Virusinfektionen Bei Organ-und Allogen Stammzell-Transplantierten: Diagnostik, Pr\u00e4vention and Therapie. Available online: https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/093-002l_S2k_Virusinfektionen-Organtransplantierte-alloge-Stammzell-Transplantierten-Diagnostik-Praevention-Therapie__2019-06.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/ajt.13684","article-title":"The \u201cABC\u201d of Virus-Specific T Cell Immunity in Solid Organ Transplantation","volume":"16","author":"Sester","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TP.0b013e3181ff8719","article-title":"The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response","volume":"91","author":"Lisboa","year":"2011","journal-title":"Transplantation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1600-6143.2004.00391.x","article-title":"Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+\/R- solid organ transplant recipients","volume":"4","author":"Humar","year":"2004","journal-title":"Am. J. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.trim.2010.06.013","article-title":"Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients","volume":"23","author":"Sun","year":"2010","journal-title":"Transpl. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Griffiths, P.D., Rothwell, E., Raza, M., Wilmore, S., Doyle, T., Harber, M., O\u2019Beirne, J., MacKinnon, S., Jones, G., and Thorburn, U. (2016). Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163722"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/cid\/cis900","article-title":"An International Multicenter Performance Analysis of Cytomegalovirus Load Tests","volume":"56","author":"Hirsch","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/JCM.39.4.1334-1338.2001","article-title":"Comparison of Quantitative and Qualitative PCR Assays for Cytomegalovirus DNA in Plasma","volume":"39","author":"Caliendo","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"ref_23","first-page":"245","article-title":"Multicenter quality control study for human cytomegalovirus DNAemia quantification","volume":"32","author":"Lilleri","year":"2009","journal-title":"New Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","article-title":"Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation","volume":"355","author":"Emery","year":"2000","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biologicals.2016.04.005","article-title":"A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology","volume":"44","author":"Fryer","year":"2016","journal-title":"Biologicals"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-6143.2009.02861.x","article-title":"Clinical Predictors of Relapse after Treatment of Primary Gastrointestinal Cytomegalovirus Disease in Solid Organ Transplant Recipients","volume":"10","author":"Eid","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/422327","article-title":"Human Cytomegalovirus Load in Plasma and Bronchoalveolar Lavage Fluid: A Longitudinal Study of Lung Transplant Recipients","volume":"190","author":"Westall","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral Drug Resistance of Human Cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1128\/JCM.01605-13","article-title":"Detection of Cytomegalovirus Drug Resistance Mutations by Next-Generation Sequencing","volume":"51","author":"Sahoo","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/342844","article-title":"Analysis and Characterization of Antiviral Drug\u2013Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients","volume":"186","author":"Lurain","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/346240","article-title":"Ganciclovir-Resistant Cytomegalovirus Disease after Allogeneic Stem Cell Transplantation: Pitfalls of Phenotypic Diagnosis by In Vitro Selection of an UL97 Mutant Strain","volume":"187","author":"Hamprecht","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2013.01.013","article-title":"Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients","volume":"57","author":"Lautenschlager","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.transproceed.2017.03.003","article-title":"Pre-emptive Therapy for Cytomegalovirus in Post-transplantation Liver Patients With Donor-Positive\/Recipient-Negative Serostatus","volume":"49","author":"Brasil","year":"2017","journal-title":"Transplant. Proc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients with Seropositive Donors: A Randomized Clinical Trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","author":"Lucey","year":"2012","journal-title":"Liver Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1432-2277.2009.00907.x","article-title":"CMV infection, diagnosis and antiviral strategies after liver transplantation","volume":"22","author":"Lautenschlager","year":"2009","journal-title":"Transpl. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.3748\/wjg.v20.i31.10658","article-title":"Cytomegalovirus infection in liver transplant recipients: Updates on clinical management","volume":"20","author":"Marcelin","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: Therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2007","journal-title":"Clin. Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.TP.0000145989.22373.03","article-title":"Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis1","volume":"78","author":"Limaye","year":"2004","journal-title":"Transplantation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.tp.0000226071.12562.1a","article-title":"Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis","volume":"81","author":"Limaye","year":"2006","journal-title":"Transplantation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/lt.20562","article-title":"Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients","volume":"12","author":"Park","year":"2005","journal-title":"Liver Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/TP.0b013e31822fa4b7","article-title":"Clinical Utility of Molecular Surveillance for Cytomegalovirus After Antiviral Prophylaxis in High-Risk Solid Organ Transplant Recipients","volume":"92","author":"Lisboa","year":"2011","journal-title":"Transplantation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/TP.0b013e318200b9f0","article-title":"Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients","volume":"91","author":"Pascual","year":"2011","journal-title":"Transplantation"},{"key":"ref_46","unstructured":"(2020, April 04). Summary of Product Characteristics: Valcyte, Available online: http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1542345229870.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1086\/339449","article-title":"Preemptive Use of Oral Ganciclovir to Prevent Cytomegalovirus Infection in Liver Transplant Patients: A Randomized, Placebo-Controlled Trial","volume":"185","author":"Paya","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/lt.23530","article-title":"Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis","volume":"18","author":"Kalil","year":"2012","journal-title":"Liver Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/lt.23460","article-title":"Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients","volume":"18","author":"Bodro","year":"2012","journal-title":"Liver Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1097\/01.TP.0000157867.98649.F5","article-title":"Indirect Outcomes Associated with Cytomegalovirus (Opportunistic Infections, Hepatitis C Virus Sequelae, and Mortality) in Liver-Transplant Recipients with the Use of Preemptive Therapy for 13 Years","volume":"79","author":"Singh","year":"2005","journal-title":"Transplantation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/lt.22249","article-title":"Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation?","volume":"17","author":"Kim","year":"2011","journal-title":"Liver Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/tri.12101","article-title":"Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients","volume":"26","author":"Onor","year":"2013","journal-title":"Transpl. Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients","volume":"9","author":"Asberg","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13543784.2017.1274733","article-title":"Letermovir for the Management of Cytomegalovirus Infection","volume":"26","author":"Bowman","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_59","unstructured":"(2020, April 09). Summary of Product Characteristics: Cymevene 2016. Available online: https:\/\/www.ema.europa.eu\/documents\/referral\/cymevene-article-30-referral-annex-iii_en.pdf."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Grayson, M.L., Cosgrove, S.E., Crowe, S., Hope, W., McCarthy, J.S., Mills, J., Mouton, J.W., and Paterson, D.L. (2017). Kucers\u2019 The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, CRC Press. Three Volume Set;.","DOI":"10.1201\/9781498747967"},{"key":"ref_61","unstructured":"Clinigen Healthcare Ltd (2014). Summary of Product Characteristics, Clinigen Healthcare Ltd."},{"key":"ref_62","unstructured":"Clinigen Healthcare Ltd (2011). Foscavir Product Information, Clinigen Healthcare Ltd."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: Results of a Phase 2a study","volume":"27","author":"Stoelben","year":"2013","journal-title":"Transpl. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e12965","DOI":"10.1111\/tid.12965","article-title":"Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)","volume":"20","author":"Chong","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","volume":"14","author":"Boivin","year":"2009","journal-title":"Antivir. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1034\/j.1399-0012.2000.140206.x","article-title":"Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients","volume":"14","author":"Sarmiento","year":"2000","journal-title":"Clin. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/ctr.12708","article-title":"Selection and use of immunosuppressive therapies after liver transplantation: Current German practice","volume":"30","author":"Herzer","year":"2016","journal-title":"Clin. Transplant."},{"key":"ref_70","unstructured":"Malvezzi, P., Jouve, T., and Rostaing, L. (2016). Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant. Exp. Clin. Transplant., 14."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantion"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Xie, X., Jiang, Y., Lai, X., Xiang, S., Shou, Z.-F., and Chen, J. (2015). mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: A meta-analysis. BMC Nephrol., 16.","DOI":"10.1186\/s12882-015-0078-5"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials","volume":"11","author":"Brennan","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.111","article-title":"Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis","volume":"265","author":"Jennings","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e13265","DOI":"10.1111\/ctr.13265","article-title":"Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia","volume":"32","author":"Knight","year":"2018","journal-title":"Clin. Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/tid.12601","article-title":"Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients","volume":"18","author":"Pascual","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"Faculty Opinions recommendation of CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials","volume":"12","author":"Mallat","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor\u2013Based Immunosuppression? A Systematic Review and Meta-Analysis","volume":"94","author":"Andrassy","year":"2012","journal-title":"Transplantion"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/8\/2352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:10Z","timestamp":1760176270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/8\/2352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":78,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["jcm9082352"],"URL":"https:\/\/doi.org\/10.3390\/jcm9082352","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]}}}